Book a Demo

About us

Our vision

Provide every person with diabetes personalized and expert level care when and where it’s needed by applying advanced algorithms and analytics designed by the world’s leading endocrinologists to all relevant patient data to deliver holistic treatment plan recommendations at the point of care and in between patient visits.

 

DreaMed’s story

The company was established in 2014, commercializing the first artificial pancreas technology which was published in the NEJM. Ever since, DreaMed Diabetes has been vigorously working on decision support tools in the diabetes management space and has become the first and only company in the world to receive FDA clearance for a decision support system using data from CGM/SMBG and insulin pumps.

Our founders are all physicians and engineers. The products we develop are based on real insights from clinical practice of diabetes specialists, physicians, and clinical researchers from the top diabetes centers worldwide.

We give great importance to privacy, security, quality, and regulatory matters and operate under our strict quality management system and in compliance with ISO 27001, GDPR and HIPAA. Our product is FDA cleared.

Today, DreaMed Diabetes is bringing the option of optimal glycemic control
to people with diabetes, wherever they are, whoever their caregiver is.

Leadership

Eran Atlas
Co Founder & CEO
LinkedIn
Professor Moshe Phillip
Co-founder, Chairman and Chief Science Officer at DreaMed Diabetes
LinkedIn
Ryan Hovey
General Manager
North America
LinkedIn
Eran Agmon
Chief Product Officer
LinkedIn
Etti Hanochi
CFO
LinkedIn
Inbal Peled
Director RA/QA
LinkedIn
Ido Muller
Co Founder and
Algorithm Team Leader
LinkedIn

Clinical Advisory Team

Dr. Revital Nimri
Co-founder and Chief Medical R&D at DreaMed Diabetes
LinkedIn PubMed
Professor Tadej Battelino
Co-founder of DreaMed Diabetes
LinkedIn PubMed
Professor Thomas Danne
Co-founder of DreaMed Diabetes
LinkedIn PubMed
Dr. Amir Tirosh
Director, Division of Endocrinology, Diabetes and Metabolism
LinkedIn PubMed

Investors

h
h
h
h
h